Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Medical Research
Published in: European Journal of Medical Research 1/2023

Open Access 01-12-2023 | Prostate Cancer | Research

Prolyl 4-hydroxylase subunit beta (P4HB) could serve as a prognostic and radiosensitivity biomarker for prostate cancer patients

Authors: Dechao Feng, Li Li, Dengxiong Li, Ruicheng Wu, Weizhen Zhu, Jie Wang, Luxia Ye, Ping Han

Published in: European Journal of Medical Research | Issue 1/2023

Login to get access

Abstract

Background

Prolyl 4-hydroxylase subunit beta (P4HB) has been reported as a suppressor in ferroptosis. However, no known empirical research has focused on exploring relationships between P4HB and prostate cancer (PCa). In this research, we initially examine the function of P4HB in PCa by thorough analysis of numerous databases and proliferation experiment.

Methods

We analyzed the correlations of P4HB expression with prognosis, clinical features, mutation genes, tumor heterogeneity, stemness, tumor immune microenvironment and PCa cells using multiple databases and in vitro experiment with R 3.6.3 software and its suitable packages.

Results

P4HB was significantly upregulated in tumor tissues compared to normal tissues and was closely related to biochemical recurrence-free survival. In terms of clinical correlations, we found that higher P4HB expression was significantly related to older age, higher Gleason score, advanced T stage and residual tumor. Surprisingly, P4HB had highly diagnostic accuracy of radiotherapy resistance (AUC 0.938). TGF beta signaling pathway and dorso ventral axis formation were upregulated in the group of low-expression P4HB. For tumor stemness, P4HB expression was positively related to EREG.EXPss and RNAss, but was negatively associated with ENHss and DNAss with statistical significance. For tumor heterogeneity, P4HB expression was positively related to MATH, but was negatively associated with tumor ploidy and microsatellite instability. For the overall assessment of TME, we observed that P4HB expression was negatively associated with all parameters, including B cells, CD4+ T cells, CD8+ T cells, neutrophils, macrophages, dendritic cells, stromal score, immune score and ESTIMATE score. Spearman analysis showed that P4HB expression was negatively related to TIDE score with statistical significance. In vitro experiment, RT-qPCR and western blot showed that three siRNAs of P4HB were effective on the knockdown of P4HB expression. Furthermore, we observed that the downregulation of P4HB had significant influence on the cell proliferation of six PCa cell lines, including LNCap, C4-2, C4-2B, PC3, DU145 and 22RV1 cells.

Conclusions

In this study, we found that P4HB might serve as a prognostic biomarker and predict radiotherapy resistance for PCa patients. Downregulation of P4HB expression could inhibit the cell proliferation of PCa cells.
Literature
1.
Xia C, Dong X, Li H, Cao M, Sun D, He S, Yang F, Yan X, Zhang S, Li N, Chen W. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl). 2022;135(5):584–90.PubMedCrossRef
2.
Yang Y. Comments on National guidelines for diagnosis and treatment of prostate cancer 2022 in China (English version). Chin J Cancer Res. 2022;34(5):456–7.PubMedPubMedCentralCrossRef
3.
Health Commission Of The People’s Republic Of China N. National guidelines for diagnosis and treatment of prostate cancer 2022 in China (English version). Chin J Cancer Res. 2022;34(3):270–88.PubMedPubMedCentralCrossRef
4.
Zi H, He SH, Leng XY, Xu XF, Huang Q, Weng H, Zhu C, Li LY, Gu JM, Li XH, Ming DJ, Li XD, Yuan S, et al. Global, regional, and national burden of kidney, bladder, and prostate cancers and their attributable risk factors, 1990–2019. Mil Med Res. 2021;8(1):60.PubMedPubMedCentral
5.
Deng Y, Qiao L, Du M, Qu C, Wan L, Li J, Huang L. Age-related macular degeneration: epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy. Genes Dis. 2022;9(1):62–79.PubMedCrossRef
6.
Li X, Ma B, Zhang W, Song Z, Zhang X, Liao M, Li X, Zhao X, Du M, Yu J, He S, Yan H. The essential role of N6-methyladenosine RNA methylation in complex eye diseases. Genes Dis. 2023;10(2):505–20.PubMedCrossRef
7.
Zhang X, Zhang Y, Sun A, Ge J. The effects of nicotinamide adenine dinucleotide in cardiovascular diseases: molecular mechanisms, roles and therapeutic potential. Genes Dis. 2022;9(4):959–72.PubMedCrossRef
8.
9.
Elsayed R, Elashiry M, Liu Y, Morandini AC, El-Awady A, Elashiry MM, Hamrick M, Cutler CW. Microbially-induced exosomes from dendritic cells promote paracrine immune senescence: novel mechanism of bone degenerative disease in mice. Aging Dis. 2023;14(1):136–51.PubMedPubMedCentralCrossRef
10.
Balakrishnan R, Azam S, Kim IS, Choi DK. Neuroprotective effects of black pepper and its bioactive compounds in age-related neurological disorders. Aging Dis. 2023;14(3):750–77.PubMedPubMedCentralCrossRef
11.
Ruiz E, Kandil E, Alhassan S, Toraih E, Errami Y, Elmageed ZYA, Zerfaoui M. An integrative multi-omics analysis of the molecular links between aging and aggressiveness in thyroid cancers. Aging Dis. 2023;14(3):992–1012.PubMedPubMedCentralCrossRef
12.
Shen W, He J, Hou T, Si J, Chen S. Common pathogenetic mechanisms underlying aging and tumor and means of interventions. Aging Dis. 2022;13(4):1063–91.PubMedPubMedCentralCrossRef
13.
14.
Liu X, Yin L, Shen S, Hou Y. Inflammation and cancer: paradoxical roles in tumorigenesis and implications in immunotherapies. Genes Dis. 2023;10(1):151–64.PubMedCrossRef
15.
Zeng Z, Lan T, Wei Y, Wei X. CCL5/CCR5 axis in human diseases and related treatments. Genes Dis. 2022;9(1):12–27.PubMedCrossRef
16.
Zhu R, Ji X, Wu X, Chen J, Li X, Jiang H, Fu H, Wang H, Lin Z, Tang X, Sun S, Li Q, Wang B, et al. Melatonin antagonizes ovarian aging via YTHDF2-MAPK-NF-kappaB pathway. Genes Dis. 2022;9(2):494–509.PubMedCrossRef
17.
Feng D, Li D, Shi X, Xiong Q, Zhang F, Wei Q, Yang L. A gene prognostic index from cellular senescence predicting metastasis and radioresistance for prostate cancer. J Transl Med. 2022;20(1):252.PubMedPubMedCentralCrossRef
18.
Feng D, Shi X, Xiong Q, Zhang F, Li D, Yang L. A gene prognostic index associated with epithelial-mesenchymal transition predicting biochemical recurrence and tumor chemoresistance for prostate cancer. Front Oncol. 2021;11:805571.PubMedCrossRef
19.
Feng D, Shi X, Zhang F, Xiong Q, Wei Q, Yang L. Mitochondria dysfunction-mediated molecular subtypes and gene prognostic index for prostate cancer patients undergoing radical prostatectomy or radiotherapy. Front Oncol. 2022;12:858479.PubMedPubMedCentralCrossRef
20.
21.
Megerian MF, Kim JS, Badreddine J, Hong SH, Ponsky LE, Shin JI, Ghayda RA. Melatonin and prostate Cancer: anti-tumor roles and therapeutic application. Aging Dis. 2023;14(3):840–57.PubMedPubMedCentralCrossRef
22.
Yang R, Zuo L, Ma H, Zhou Y, Zhou P, Wang L, Wang M, Latif M, Kong L. Downregulation of nc886 contributes to prostate cancer cell invasion and TGFbeta1-induced EMT. Genes Dis. 2022;9(4):1086–98.PubMedCrossRef
23.
Xu Z, Huang J, Gao M, Guo G, Zeng S, Chen X, Wang X, Gong Z, Yan Y. Current perspectives on the clinical implications of oxidative RNA damage in aging research: challenges and opportunities. Geroscience. 2021;43(2):487–505.PubMedCrossRef
24.
25.
26.
Feng D, Liu S, Li D, Han P, Wei W. Analysis of conventional versus advanced pelvic floor muscle training in the management of urinary incontinence after radical prostatectomy: a systematic review and meta-analysis of randomized controlled trials. Transl Androl Urol. 2020;9(5):2031–45.PubMedPubMedCentralCrossRef
27.
Feng D, Shi X, Xiong Q, Zhang F, Li D, Wei W, Yang L. A ferroptosis-related gene prognostic index associated with biochemical recurrence and radiation resistance for patients with prostate cancer undergoing radical radiotherapy. Front Cell Dev Biol. 2022;10:803766.PubMedPubMedCentralCrossRef
28.
Feng D, Shi X, Zhang F, Xiong Q, Wei Q, Yang L. Energy metabolism-related gene prognostic index predicts biochemical recurrence for patients with prostate cancer undergoing radical prostatectomy. Front Immunol. 2022;13:839362.PubMedPubMedCentralCrossRef
29.
30.
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, Morrison B 3rd, Stockwell BR. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060–72.PubMedPubMedCentralCrossRef
31.
32.
Zhao L, Zhou X, Xie F, Zhang L, Yan H, Huang J, Zhang C, Zhou F, Chen J, Zhang L. Ferroptosis in cancer and cancer immunotherapy. Cancer Commun. 2022;42(2):88–116.CrossRef
33.
34.
Lu C, Tan C, Ouyang H, Chen Z, Yan Z, Zhang M. Ferroptosis in intracerebral hemorrhage: a panoramic perspective of the metabolism mechanism and theranostics. Aging Dis. 2022;13(5):1348–64.PubMedPubMedCentralCrossRef
35.
36.
Mortensen MM, Hoyer S, Lynnerup AS, Orntoft TF, Sorensen KD, Borre M, Dyrskjot L. Expression profiling of prostate cancer tissue delineates genes associated with recurrence after prostatectomy. Sci Rep. 2015;5:16018.PubMedPubMedCentralCrossRef
37.
Kuner R, Falth M, Pressinotti NC, Brase JC, Puig SB, Metzger J, Gade S, Schafer G, Bartsch G, Steiner E, Klocker H, Sultmann H. The maternal embryonic leucine zipper kinase (MELK) is upregulated in high-grade prostate cancer. J Mol Med (Berl). 2013;91(2):237–48.PubMedCrossRef
38.
Penney KL, Sinnott JA, Tyekucheva S, Gerke T, Shui IM, Kraft P, Sesso HD, Freedman ML, Loda M, Mucci LA, Stampfer MJ. Association of prostate cancer risk variants with gene expression in normal and tumor tissue. Cancer Epidemiol Biomarkers Prev. 2015;24(1):255–60.PubMedCrossRef
39.
Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B, Liu XS. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–10.PubMedPubMedCentralCrossRef
40.
Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B, Varambally S. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649–58.PubMedPubMedCentralCrossRef
41.
Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–102.PubMedPubMedCentralCrossRef
42.
Cojoc M, Peitzsch C, Kurth I, Trautmann F, Kunz-Schughart LA, Telegeev GD, Stakhovsky EA, Walker JR, Simin K, Lyle S, Fuessel S, Erdmann K, Wirth MP, et al. Aldehyde dehydrogenase Is regulated by beta-catenin/TCF and promotes radioresistance in prostate cancer progenitor cells. Cancer Res. 2015;75(7):1482–94.PubMedCrossRef
43.
Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463(7283):899–905.PubMedPubMedCentralCrossRef
44.
Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson A, Kampf C, Sjostedt E, Asplund A, Olsson I, Edlund K, Lundberg E, et al. Proteomics tissue-based map of the human proteome. Science. 2015;347(6220):1260419.PubMedCrossRef
45.
46.
Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, Franz M, Grouios C, Kazi F, Lopes CT, Maitland A, Mostafavi S, Montojo J, et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 2010;38:W214-220.PubMedPubMedCentralCrossRef
47.
Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, Doncheva NT, Legeay M, Fang T, Bork P, Jensen LJ, von Mering C. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res. 2021;49(D1):D605–12.PubMedCrossRef
48.
49.
Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011;27(12):1739–40.PubMedPubMedCentralCrossRef
50.
Li B, Severson E, Pignon JC, Zhao H, Li T, Novak J, Jiang P, Shen H, Aster JC, Rodig S, Signoretti S, Liu JS, Liu XS. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016;17(1):174.PubMedPubMedCentralCrossRef
51.
Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, Trevino V, Shen H, Laird PW, Levine DA, Carter SL, Getz G, Stemke-Hale K, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.PubMedCrossRef
52.
Zeng D, Ye Z, Shen R, Yu G, Wu J, Xiong Y, Zhou R, Qiu W, Huang N, Sun L, Li X, Bin J, Liao Y, et al. IOBR: multi-omics immuno-oncology biological research to decode tumor microenvironment and signatures. Front Immunol. 2021;12:687975.PubMedPubMedCentralCrossRef
53.
Ru B, Wong CN, Tong Y, Zhong JY, Zhong SSW, Wu WC, Chu KC, Wong CY, Lau CY, Chen I, Chan NW, Zhang J. TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics. 2019;35(20):4200–2.PubMedCrossRef
54.
Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, Li Z, Traugh N, Bu X, Li B, Liu J, Freeman GJ, Brown MA, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550–8.PubMedPubMedCentralCrossRef
55.
Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang T-H, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, et al. The immune landscape of cancer. Immunity. 2018;48(4):812-830.e814.PubMedPubMedCentralCrossRef
56.
Bonneville R, Krook MA, Kautto EA, Miya J, Wing MR, Chen H-Z, Reeser JW, Yu L, Roychowdhury S. Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol. 2017;2017:1.
57.
Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, Kamińska B, Huelsken J, Omberg L, Gevaert O, Colaprico A, Czerwińska P, Mazurek S, et al. Machine learning identifies stemness features associated with oncogenic dedifferentiation. Cell. 2018;173(2):338-354.e315.PubMedPubMedCentralCrossRef
58.
Feng D, Wang J, Shi X, Li D, Wei W, Han P. Membrane tension-mediated stiff and soft tumor subtypes closely associated with prognosis for prostate cancer patients. Eur J Med Res. 2023;28(1):172.PubMedPubMedCentralCrossRef
59.
Shi X, Feng D, Li D, Han P, Yang L, Wei W. A pan-cancer analysis of the oncogenic and immunological roles of apolipoprotein F (APOF) in human cancer. Eur J Med Res. 2023;28(1):190.PubMedPubMedCentralCrossRef
60.
Feng D, Shi X, Zhu W, Zhang F, Li D, Han P, Wei Q, Yang L. A pan-cancer analysis of the oncogenic role of leucine zipper protein 2 in human cancer. Exp Hematol Oncol. 2022;11(1):55.PubMedPubMedCentralCrossRef
61.
Zhu W, Feng D, Shi X, Li D, Wei Q, Yang L. A pan-cancer analysis of the oncogenic role of zinc finger protein 419 in human cancer. Front Oncol. 2022;12:1042118.PubMedPubMedCentralCrossRef
62.
Qian Y, Feng D, Wang J, Wei W, Wei Q, Han P, Yang L. Establishment of cancer-associated fibroblasts-related subtypes and prognostic index for prostate cancer through single-cell and bulk RNA transcriptome. Sci Rep. 2023;13(1):9016.PubMedPubMedCentralCrossRef
63.
Liu CJ, Hu FF, Xia MX, Han L, Zhang Q, Guo AY. GSCALite: a web server for gene set cancer analysis. Bioinformatics. 2018;34(21):3771–2.PubMedCrossRef
64.
Feng D, Zhu W, Shi X, Wei W, Han P, Wei Q, Yang L. Leucine zipper protein 2 serves as a prognostic biomarker for prostate cancer correlating with immune infiltration and epigenetic regulation. Heliyon. 2022;8(10):e10750.PubMedPubMedCentralCrossRef
65.
Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, Fulda S, Gascon S, Hatzios SK, Kagan VE, Noel K, Jiang X, Linkermann A, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171(2):273–85.PubMedPubMedCentralCrossRef
66.
67.
Wang L, Chen X, Yan C. Ferroptosis: an emerging therapeutic opportunity for cancer. Genes Dis. 2022;9(2):334–46.PubMedCrossRef
68.
Sun Y, He Y, Tong J, Liu D, Zhang H, He T, Bi Y. All-trans retinoic acid inhibits the malignant behaviors of hepatocarcinoma cells by regulating ferroptosis. Genes Dis. 2022;9(6):1742–56.PubMedPubMedCentralCrossRef
69.
Pu F, Chen F, Zhang Z, Shi D, Zhong B, Lv X, Tucker AB, Fan J, Li AJ, Qin K, Hu D, Chen C, Wang H, et al. Ferroptosis as a novel form of regulated cell death: implications in the pathogenesis, oncometabolism and treatment of human cancer. Genes Dis. 2022;9(2):347–57.PubMedCrossRef
70.
Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji AF, Clish CB, Brown LM, Girotti AW, Cornish VW, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156(1–2):317–31.PubMedPubMedCentralCrossRef
71.
Doll S, Freitas FP, Shah R, Aldrovandi M, da Silva MC, Ingold I, Goya Grocin A, Xavier da Silva TN, Panzilius E, Scheel CH, Mourao A, Buday K, Sato M, et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature. 2019;575(7784):693–8.PubMedCrossRef
72.
Bersuker K, Hendricks JM, Li Z, Magtanong L, Ford B, Tang PH, Roberts MA, Tong B, Maimone TJ, Zoncu R, Bassik MC, Nomura DK, Dixon SJ, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature. 2019;575(7784):688–92.PubMedPubMedCentralCrossRef
73.
Shimada K, Skouta R, Kaplan A, Yang WS, Hayano M, Dixon SJ, Brown LM, Valenzuela CA, Wolpaw AJ, Stockwell BR. Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis. Nat Chem Biol. 2016;12(7):497–503.PubMedPubMedCentralCrossRef
74.
Yang WS, Stockwell BR. Ferroptosis: death by lipid peroxidation. Trends Cell Biol. 2016;26(3):165–76.PubMedCrossRef
75.
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33.PubMedCrossRef
76.
Tousignant KD, Rockstroh A, Poad BLJ, Talebi A, Young RSE, Taherian Fard A, Gupta R, Zang T, Wang C, Lehman ML, Swinnen JV, Blanksby SJ, Nelson CC, et al. Therapy-induced lipid uptake and remodeling underpin ferroptosis hypersensitivity in prostate cancer. Cancer Metab. 2020;8:11.PubMedPubMedCentralCrossRef
77.
Ghoochani A, Hsu EC, Aslan M, Rice MA, Nguyen HM, Brooks JD, Corey E, Paulmurugan R, Stoyanova T. Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer. Cancer Res. 2021;81(6):1583–94.PubMedPubMedCentralCrossRef
78.
79.
Qin Z, Ou S, Xu L, Sorensen K, Zhang Y, Hu DP, Yang Z, Hu WY, Chen F, Prins GS. Design and synthesis of isothiocyanate-containing hybrid androgen receptor (AR) antagonist to downregulate AR and induce ferroptosis in GSH-Deficient prostate cancer cells. Chem Biol Drug Des. 2021;97(5):1059–78.PubMedPubMedCentralCrossRef
80.
Karala AR, Ruddock LW. Bacitracin is not a specific inhibitor of protein disulfide isomerase. FEBS J. 2010;277(11):2454–62.PubMedCrossRef
81.
Wang X, Bai Y, Zhang F, Yang Y, Feng D, Li A, Yang Z, Li D, Tang Y, Wei X, Wei W, Han P. Targeted inhibition of P4HB promotes cell sensitivity to gemcitabine in urothelial carcinoma of the bladder. Onco Targets Ther. 2020;13:9543–58.PubMedPubMedCentralCrossRef
82.
Chen YC, Oses-Prieto JA, Pope LE, Burlingame AL, Dixon SJ, Renslo AR. Reactivity-based probe of the iron(II)-dependent interactome identifies new cellular modulators of ferroptosis. J Am Chem Soc. 2020;142(45):19085–93.PubMedPubMedCentralCrossRef
83.
Pan CF, Wei K, Ma ZJ, He YZ, Huang JJ, Guo ZZ, Chen ZP, Barr MP, Shackelford RE, Xia Y, Wang J. CircP4HB regulates ferroptosis via SLC7A11-mediated glutathione synthesis in lung adenocarcinoma. Transl Lung Cancer Res. 2022;11(3):366–80.PubMedPubMedCentralCrossRef
84.
Sun S, Kiang KMY, Ho ASW, Lee D, Poon MW, Xu FF, Pu JKS, Kan ANC, Lee NPY, Liu XB, Man K, Day PJR, Lui WM, et al. Endoplasmic reticulum chaperone prolyl 4-hydroxylase, beta polypeptide (P4HB) promotes malignant phenotypes in glioma via MAPK signaling. Oncotarget. 2017;8(42):71911–23.PubMedPubMedCentralCrossRef
85.
Wen Z, Sun Q, Shan Y, Xie W, Ding Y, Wang W, Ye R, Xiao W, Li Y. Endoplasmic reticulum stress in osteoarthritis: a novel perspective on the pathogenesis and treatment. Aging Dis. 2023;14(2):283–6.PubMedPubMedCentral
86.
Gaschler MM, Hu F, Feng H, Linkermann A, Min W, Stockwell BR. Determination of the subcellular localization and mechanism of action of ferrostatins in suppressing ferroptosis. ACS Chem Biol. 2018;13(4):1013–20.PubMedPubMedCentralCrossRef
87.
Banhegyi G, Baumeister P, Benedetti A, Dong D, Fu Y, Lee AS, Li J, Mao C, Margittai E, Ni M, Paschen W, Piccirella S, Senesi S, et al. Endoplasmic reticulum stress. Ann N Y Acad Sci. 2007;1113:58–71.PubMedCrossRef
88.
Pachikov AN, Gough RR, Christy CE, Morris ME, Casey CA, LaGrange CA, Bhat G, Kubyshkin AV, Fomochkina II, Zyablitskaya EY, Makalish TP, Golubinskaya EP, Davydenko KA, et al. The non-canonical mechanism of ER stress-mediated progression of prostate cancer. J Exp Clin Cancer Res. 2021;40(1):289.PubMedPubMedCentralCrossRef
89.
Dixon SJ, Patel DN, Welsch M, Skouta R, Lee ED, Hayano M, Thomas AG, Gleason CE, Tatonetti NP, Slusher BS, Stockwell BR. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife. 2014;3:e02523.PubMedPubMedCentralCrossRef
90.
Lee YS, Lee DH, Choudry HA, Bartlett DL, Lee YJ. Ferroptosis-induced endoplasmic reticulum stress: cross-talk between ferroptosis and apoptosis. Mol Cancer Res. 2018;16(7):1073–6.PubMedPubMedCentralCrossRef
91.
Luo B, Lee AS. The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies. Oncogene. 2013;32(7):805–18.PubMedCrossRef
92.
Ma Y, Hendershot LM. The role of the unfolded protein response in tumour development: friend or foe? Nat Rev Cancer. 2004;4(12):966–77.PubMedCrossRef
93.
Jin Y, Saatcioglu F. Targeting the unfolded protein response in hormone-regulated cancers. Trends Cancer. 2020;6(2):160–71.PubMedCrossRef
94.
Sheng X, Arnoldussen YJ, Storm M, Tesikova M, Nenseth HZ, Zhao S, Fazli L, Rennie P, Risberg B, Waehre H, Danielsen H, Mills IG, Jin Y, et al. Divergent androgen regulation of unfolded protein response pathways drives prostate cancer. EMBO Mol Med. 2015;7(6):788–801.PubMedPubMedCentralCrossRef
95.
Stelloo S, Linder S, Nevedomskaya E, Valle-Encinas E, de Rink I, Wessels LFA, van der Poel H, Bergman AM, Zwart W. Androgen modulation of XBP1 is functionally driving part of the AR transcriptional program. Endocr Relat Cancer. 2020;27(2):67–79.PubMedCrossRef
96.
Johnson GG, White MC, Grimaldi M. Stressed to death: targeting endoplasmic reticulum stress response induced apoptosis in gliomas. Curr Pharm Des. 2011;17(3):284–92.PubMedPubMedCentralCrossRef
97.
Boyce M, Yuan J. Cellular response to endoplasmic reticulum stress: a matter of life or death. Cell Death Differ. 2006;13(3):363–73.PubMedCrossRef
98.
Virrey JJ, Dong D, Stiles C, Patterson JB, Pen L, Ni M, Schonthal AH, Chen TC, Hofman FM, Lee AS. Stress chaperone GRP78/BiP confers chemoresistance to tumor-associated endothelial cells. Mol Cancer Res. 2008;6(8):1268–75.PubMedPubMedCentralCrossRef
99.
Fonseca C, Soiffer R, Ho V, Vanneman M, Jinushi M, Ritz J, Neuberg D, Stone R, DeAngelo D, Dranoff G. Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction. Blood. 2009;113(8):1681–8.PubMedPubMedCentralCrossRef
100.
Kremer DM, Nelson BS, Lin L, Yarosz EL, Halbrook CJ, Kerk SA, Sajjakulnukit P, Myers A, Thurston G, Hou SW, Carpenter ES, Andren AC, Nwosu ZC, et al. GOT1 inhibition promotes pancreatic cancer cell death by ferroptosis. Nat Commun. 2021;12(1):4860.PubMedPubMedCentralCrossRef
101.
Seibt TM, Proneth B, Conrad M. Role of GPX4 in ferroptosis and its pharmacological implication. Free Radic Biol Med. 2019;133:144–52.PubMedCrossRef
102.
103.
Feng D, Xiong Q, Wei Q, Yang L. Cellular landscape of tumour microenvironment in prostate cancer. Immunology. 2023;168(2):199–202.PubMedCrossRef
104.
105.
Yang Y, Gu J, Li X, Xue C, Ba L, Gao Y, Zhou J, Bai C, Sun Z, Zhao RC. HIF-1alpha promotes the migration and invasion of cancer-associated fibroblasts by miR-210. Aging Dis. 2021;12(7):1794–807.PubMedPubMedCentralCrossRef
106.
You T, Tang H, Wu W, Gao J, Li X, Li N, Xu X, Xing J, Ge H, Xiao Y, Guo J, Wu B, Li X, et al. POSTN secretion by extracellular matrix cancer-associated fibroblasts (eCAFs) correlates with poor ICB response via macrophage chemotaxis activation of Akt signaling pathway in gastric cancer. Aging Dis. 2023. https://​doi.​org/​10.​14336/​AD.​2023.​0503.CrossRefPubMed
107.
108.
109.
110.
Wang W, Green M, Choi JE, Gijon M, Kennedy PD, Johnson JK, Liao P, Lang X, Kryczek I, Sell A, Xia H, Zhou J, Li G, et al. CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569(7755):270–4.PubMedPubMedCentralCrossRef
111.
Wu P, Xiang T, Wang J, Lv R, Ma S, Yuan L, Wu G, Che X. Identification of immunization-related new prognostic biomarkers for papillary renal cell carcinoma by integrated bioinformatics analysis. BMC Med Genomics. 2021;14(1):241.PubMedPubMedCentralCrossRef
112.
Robinson RM, Reyes L, Duncan RM, Bian H, Strobel ED, Hyman SL, Reitz AB, Dolloff NG. Tuning isoform selectivity and bortezomib sensitivity with a new class of alkenyl indene PDI inhibitor. Eur J Med Chem. 2020;186:111906.PubMedCrossRef
113.
Wan C, Sun Y, Tian Y, Lu L, Dai X, Meng J, Huang J, He Q, Wu B, Zhang Z, Jiang K, Hu D, Wu G, et al. Irradiated tumor cell-derived microparticles mediate tumor eradication via cell killing and immune reprogramming. Sci Adv. 2020;6(13):eaay9789.PubMedPubMedCentralCrossRef
114.
Zhang J, Yang J, Zuo T, Ma S, Xokrat N, Hu Z, Wang Z, Xu R, Wei Y, Shen Q. Heparanase-driven sequential released nanoparticles for ferroptosis and tumor microenvironment modulations synergism in breast cancer therapy. Biomaterials. 2021;266:120429.PubMedCrossRef
Metadata
Title
Prolyl 4-hydroxylase subunit beta (P4HB) could serve as a prognostic and radiosensitivity biomarker for prostate cancer patients
Authors
Dechao Feng
Li Li
Dengxiong Li
Ruicheng Wu
Weizhen Zhu
Jie Wang
Luxia Ye
Ping Han
Publication date
01-12-2023
Publisher
BioMed Central
Published in
European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI
https://doi.org/10.1186/s40001-023-01215-2

Other articles of this Issue 1/2023

European Journal of Medical Research 1/2023 Go to the issue

Review

The potential roles of cigarette smoke-induced extracellular vesicles in oral leukoplakia

Research

Acute renal injury after aortic arch reconstruction with cardiopulmonary bypass for children: prediction models by machine learning of a retrospective cohort study

Research

Low body temperature and mortality in critically ill patients with coronary heart disease: a retrospective analysis from MIMIC-IV database

Research

Resveratrol: a potential medication for the prevention and treatment of varicella zoster virus-induced ischemic stroke

Research

Prediction factors and clinical significance of different types of hemorrhagic transformation after intravenous thrombolysis

Review

Comparative efficacy of nine exercise methods on the prognosis in chronic kidney disease patients with hemodialysis: a systematic review and network meta-analysis